Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating
Craig-Hallum Gives a Buy Rating to Harrow Health (HROW)
B.Riley Financial Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $50
Harrow Health's Promising Pipeline and Strategic Positioning Spur Buy Rating
Harrow Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Outset Medical (OM), Certara (CERT) and Harrow Health (HROW)
Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating
Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating
B.Riley Financial Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $29
Harrow Health's Strong Market Performance and Growth Prospects Justify Buy Rating
B.Riley Financial Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $29
Harrow Health's Growth Trajectory: A Strong Buy Rating With a $29 Price Target
Harrow Health (HROW) Gets a Buy From Craig-Hallum
Harrow Analyst Ratings
Harrow Analyst Ratings
Harrow Analyst Ratings
Harrow Health's Promising Growth Trajectory and Strong Financial Outlook Reinforce Buy Rating
Harrow Health (HROW) Receives a Buy From Lake Street
Craig-Hallum Keeps Their Buy Rating on Harrow Health (HROW)
Analysts Offer Insights on Healthcare Companies: Rapid Micro Biosystems (RPID), COMPASS Pathways (CMPS) and Harrow Health (HROW)